The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

Source: Second-line afatinib significantly ...d and neck cancer, phase III trial shows


David Cottle

UBB Owner & Administrator